108 related articles for article (PubMed ID: 2469694)
1. Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy.
Schiogolev SA; Goetzl EJ; Urba WJ; Longo DL
J Clin Immunol; 1989 Mar; 9(2):169-73. PubMed ID: 2469694
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant ascites with allogeneic and autologous lymphokine-activated killer cells.
Kamada M; Sakamoto Y; Furumoto H; Mori K; Daitoh T; Irahara M; Aono T; Nii A; Yanagawa H; Sone S
Gynecol Oncol; 1989 Jul; 34(1):34-7. PubMed ID: 2786830
[TBL] [Abstract][Full Text] [Related]
5. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
6. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations.
Urba WJ; Clark JW; Steis RG; Bookman MA; Smith JW; Beckner S; Maluish AE; Rossio JL; Rager H; Ortaldo JR
J Natl Cancer Inst; 1989 Apr; 81(8):602-11. PubMed ID: 2495368
[TBL] [Abstract][Full Text] [Related]
8. The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells.
Ottow RT; Eggermont AM; Steller EP; Sugarbaker PH
Cancer; 1987 Oct; 60(7):1465-73. PubMed ID: 3497705
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models.
Ottow RT; Steller EP; Sugarbaker PH; Wesley RA; Rosenberg SA
Cell Immunol; 1987 Feb; 104(2):366-76. PubMed ID: 3493081
[TBL] [Abstract][Full Text] [Related]
11. Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia.
Qin ZL; Yang LQ; Li N; Yue JN; Wu BS; Tang YZ; Guo YN; Lai GH; Ni JX
Clin Neurol Neurosurg; 2016 Apr; 143():111-5. PubMed ID: 26918582
[TBL] [Abstract][Full Text] [Related]
12. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
Yeung AW; Pang YK; Tsang YC; Wong SW; Leung JS
Cancer; 1993 Jun; 71(11):3633-9. PubMed ID: 8387882
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
14. [Biotherapy of malignant peritoneal effusions in ovarian carcinoma].
Titov KS; Gritsaĭ AN; Kiselevskiĭ MV; Sel'chuk VIu; Timova GV; Kuchmezov EKh; Antonov AK
Vopr Onkol; 2011; 57(4):470-4. PubMed ID: 22191236
[TBL] [Abstract][Full Text] [Related]
15. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
16. Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells.
Oomori K; Kikuchi Y; Miyauchi M; Kita T; Iwano I; Kizawa I; Hirata J; Kuki E
J Cancer Res Clin Oncol; 1989; 115(3):217-20. PubMed ID: 2787797
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptides in the saliva of healthy subjects.
Dawidson I; Blom M; Lundeberg T; Theodorsson E; Angmar-Månsson B
Life Sci; 1997; 60(4-5):269-78. PubMed ID: 9010482
[TBL] [Abstract][Full Text] [Related]
18. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
19. Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes.
Dallos A; Kiss M; Polyánka H; Dobozy A; Kemény L; Husz S
Neuropeptides; 2006 Aug; 40(4):251-63. PubMed ID: 16904178
[TBL] [Abstract][Full Text] [Related]
20. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
Kanaoka Y; Umesaki N
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
